Seattle Children’s cancer survivor becomes a caregiver
September 25, 2018
The motivation behind Seahawks’ Russell Wilson visiting Seattle...
October 4, 2018

Endocyte becomes first Purdue startup to reach $1.5B in value

Endocyte’s value recently reached about $1.5 billion. The company’s primary technology focuses targeted therapeutics for personalized cancer treatment. Endocyte’s second major drug under development is a CAR-T cell immunotherapy.

Endocyte’s value recently reached about $1.5 billion. The company’s primary technology focuses targeted therapeutics for personalized cancer treatment. Endocyte’s second major drug under development is a CAR-T cell immunotherapy. “We’re working with Dr. Mike Jensen of Seattle Children’s Research Institute to advance this CAR-T cell therapy into the clinic for the treatment of osteosarcoma, which is typically a pediatric bone cancer,” said Philip Low, Endocyte’s chief science officer. “The CAR-T cell program, like our radioligand therapy program, is tumor targeted, and so we believe it could be useful for other types of cancers. There is a significant need to develop a therapy for this very challenging disease, and we have chosen to work with Seattle Children’s Research Institute, where the expertise in CAR-T cell therapies and osteosarcoma are widely recognized.”

Source: Morningstar